Nadav Ahituv

Last updated

Nadav Ahituv is the Director for the Institute for Human Genetics at the University of California, San Francisco (USCF). [1] [2] [3] He is also a Professor in the Department of Bioengineering and Therapeutic Sciences and leads the Ahituv Lab at University of California, San Francisco (USCF). [1] [4]

Contents

Early life and education

Ahituv received his PhD with distinction in human genetics from Tel-Aviv University, where he worked on hereditary hearing loss. [1] [3] [2]

Research

Ahituv developed cis-regulation therapy (CRT) for genetic diseases that are caused due to changes in gene dosage [5] [6] and adipose manipulation transplantation (AMT) that engineers fat cells and implants them for therapeutic benefits. [7]

The Ahituv Lab investigates gene regulatory elements and their relationship to human diversity and disease. [4] His lab also focuses on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes, including morphological differences between species, drug response, and human disease. [8] The lab is one of the developers of massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements. [9]

Awards and honors

In 2014, Ahituv received the ASCPT Leon I. Goldberg young investigator award from The American Society for Clinical Pharmacology and Therapeutics. [10] [1] In 2024, Ahituv received the Scientific Achievement Award from the The American Society of Human Genetics (ASHG). [11]

Related Research Articles

<span class="mw-page-title-main">Genetic testing</span> Medical test

Genetic testing, also known as DNA testing, is used to identify changes in DNA sequence or chromosome structure. Genetic testing can also include measuring the results of genetic changes, such as RNA analysis as an output of gene expression, or through biochemical analysis to measure specific protein output. In a medical setting, genetic testing can be used to diagnose or rule out suspected genetic disorders, predict risks for specific conditions, or gain information that can be used to customize medical treatments based on an individual's genetic makeup. Genetic testing can also be used to determine biological relatives, such as a child's biological parentage through DNA paternity testing, or be used to broadly predict an individual's ancestry. Genetic testing of plants and animals can be used for similar reasons as in humans, to gain information used for selective breeding, or for efforts to boost genetic diversity in endangered populations.

<span class="mw-page-title-main">Human genetic enhancement</span> Technologies to genetically improve human bodies

Human genetic enhancement or human genetic engineering refers to human enhancement by means of a genetic modification. This could be done in order to cure diseases, prevent the possibility of getting a particular disease, to improve athlete performance in sporting events, or to change physical appearance, metabolism, and even improve physical capabilities and mental faculties such as memory and intelligence. These genetic enhancements may or may not be done in such a way that the change is heritable.

<span class="mw-page-title-main">Epigenome</span> Biological term

In biology, the epigenome of an organism is the collection of chemical changes to its DNA and histone proteins that affects when, where, and how the DNA is expressed; these changes can be passed down to an organism's offspring via transgenerational epigenetic inheritance. Changes to the epigenome can result in changes to the structure of chromatin and changes to the function of the genome. The human epigenome, including DNA methylation and histone modification, is maintained through cell division. The epigenome is essential for normal development and cellular differentiation, enabling cells with the same genetic code to perform different functions. The human epigenome is dynamic and can be influenced by environmental factors such as diet, stress, and toxins.

<span class="mw-page-title-main">Regulator gene</span> Gene involved in controlling expression of other genes

In genetics, a regulator gene, regulator, or regulatory gene is a gene involved in controlling the expression of one or more other genes. Regulatory sequences, which encode regulatory genes, are often at the five prime end (5') to the start site of transcription of the gene they regulate. In addition, these sequences can also be found at the three prime end (3') to the transcription start site. In both cases, whether the regulatory sequence occurs before (5') or after (3') the gene it regulates, the sequence is often many kilobases away from the transcription start site. A regulator gene may encode a protein, or it may work at the level of RNA, as in the case of genes encoding microRNAs. An example of a regulator gene is a gene that codes for a repressor protein that inhibits the activity of an operator.

<span class="mw-page-title-main">Neil Risch</span> American geneticist

Neil Risch is an American human geneticist and professor at the University of California, San Francisco (UCSF). Risch is the Lamond Family Foundation Distinguished Professor in Human Genetics, Founding Director of the Institute for Human Genetics, and Professor of Epidemiology and Biostatistics at UCSF. He specializes in statistical genetics, genetic epidemiology and population genetics.

<span class="mw-page-title-main">Mary-Claire King</span> American geneticist

Mary-Claire King is an American geneticist. She was the first to show that breast cancer can be inherited due to mutations in the gene she called BRCA1. She studies human genetics and is particularly interested in genetic heterogeneity and complex traits. She studies the interaction of genetics and environmental influences and their effects on human conditions such as breast and ovarian cancer, inherited deafness, schizophrenia, HIV, systemic lupus erythematosus and rheumatoid arthritis. She has been the American Cancer Society Professor of the Department of Genome Sciences and of Medical Genetics in the Department of Medicine at the University of Washington since 1995.

<span class="mw-page-title-main">Eric Schadt</span> American scientist

Eric Emil Schadt is an American mathematician and computational biologist. He is founder and former chief executive officer of Sema4, a patient-centered health intelligence company, and dean for precision medicine and Mount Sinai Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai. He was previously founding director of the Icahn Institute for Genomics and Multiscale Biology and chair of the Department of Genetics and Genomics Sciences at the Icahn School of Medicine at Mount Sinai.

Ying-Hui Fu is a Taiwanese-American biologist and human geneticist who has made important contributions to understanding the genetics of many neurological disorders. Her chief discoveries include describing Mendelian sleep phenotypes, identifying causative genes and mutations for circadian rhythm disorders, and characterizing genetic forms of demyelinating degenerative disorders. Fu is currently a professor of neurology at the University of California, San Francisco. She was elected to the US National Academy of Sciences in 2018.

Stuart Holland Orkin is an American physician, stem cell biologist and researcher in pediatric hematology-oncology. He is the David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School. Orkin's research has focused on the genetic basis of blood disorders. He is a member of the National Academy of Sciences and the Institute of Medicine, and an Investigator of the Howard Hughes Medical Institute.

Wendy K. Chung is an American clinical and molecular geneticist and physician. She is the Chair of the Department of Pediatrics at Boston Children's Hospital and is on the faculty at Harvard Medical School. She is the author of 700 peer-reviewed articles and 75 chapters and has won several awards as a physician, researcher, and professor. Chung helped to initiate a new form of newborn screening for spinal muscular atrophy which is used nationally and was among the plaintiffs in the Supreme Court case which banned gene patenting.

Mark Joseph Daly is Director of the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki, a Professor of Genetics at Harvard Medical School, Chief of the Analytic and Translational Genetic Unit at Massachusetts General Hospital, and a member of the Broad Institute of MIT and Harvard. In the early days of the Human Genome Project, Daly helped develop the genetic model by which linkage disequilibrium could be used to map the haplotype structure of the human genome. In addition, he developed statistical methods to find associations between genes and disorders such as Crohn's disease, inflammatory bowel disease, autism and schizophrenia.

<span class="mw-page-title-main">Manolis Kellis</span> Greek-born computational biologist

Manolis Kellis is a professor of Computer Science and Computational Biology at the Massachusetts Institute of Technology (MIT) and a member of the Broad Institute of MIT and Harvard. He is the head of the Computational Biology Group at MIT and is a Principal Investigator in the Computer Science and Artificial Intelligence Lab (CSAIL) at MIT.

James Francis Gusella is a Canadian molecular biologist and geneticist known for his work on Huntington's disease and other neurodegenerative diseases in humans. He is the Bullard Professor of Neurogenetics in the Department of Genetics at Harvard Medical School and an investigator at the Center for Genomic Medicine at the Mass General Research Institute.

Sarah Anne Tishkoff is an American geneticist and the David and Lyn Silfen Professor in the Department of Genetics and Biology at the University of Pennsylvania. She also serves as a director for the American Society of Human Genetics and is an associate editor at PLOS Genetics, G3, and Genome Research. She is also a member of the scientific advisory board at the David and Lucile Packard Foundation.

<span class="mw-page-title-main">Charles Rotimi</span> Nigerian geneticist

Charles Nohuoma Rotimi is the Scientific Director of the National Human Genome Research Institute (NHGRI). He joined the National Institutes of Health (NIH) in 2008 as the inaugural Director of the Trans-NIH Center for Research in Genomics and Global Health and was also the chief of the NHGRI's Metabolic, Cardiovascular, and Inflammatory Disease Genomics Branch. He works to ensure that population genetics include genomes from African populations and founded the African Society of Human Genetics in 2003 and was elected its first president. Rotimi was instrumental in the launch of the Human Heredity and Health in Africa (H3Africa) with the NIH and the Wellcome Trust. He was elected to the National Academy of Medicine in 2018.

<span class="mw-page-title-main">Emmanouil Dermitzakis</span> Greek human genetics researcher

Emmanouil Theophilos Dermitzakis is a Greek human geneticist and professor in the Department of Genetic Medicine and Development at the University of Geneva, where he is also Director of the Health 2030 Genome Center. He is an ISI Highly Cited Researcher and an elected member of the European Molecular Biology Organization. He is a member of the Swiss Institute of Bioinformatics, where his research group is focused on the genetics and genomics of complex traits in humans. He has joined GlaxoSmithKline as Vice President, Computational Biology in R&D.

<span class="mw-page-title-main">Kelly A. Frazer</span> American physician

Kelly A Frazer is a Professor of Pediatrics in the Medical School at the University of California, San Diego, Chief of the Division of Genome Information Sciences and Director of the Institute for Genomic Medicine.

Kiran Musunuru is an American cardiologist who is a Professor of Medicine at the University of Pennsylvania Perelman School of Medicine. He researches the genetics and genomics of cardiovascular and metabolic diseases. Musunuru is a leading expert in the field of gene-editing.

Alexander (Sasha) Gusev is a computational biologist and an associate professor of medicine at Harvard Medical School and the Dana Farber Cancer Institute.

<span class="mw-page-title-main">Wylie Burke</span> American geneticist

Wylie Burke is a Professor Emerita and former Chair of the Department of Bioethics and Humanities at the University of Washington and a founding co-director of the Northwest-Alaska Pharmacogenomics Research Network, which partners with underserved populations in the Pacific Northwest and Alaska.

References

  1. 1 2 3 4 "Nadav Ahituv | UCSF Profiles". profiles.ucsf.edu. Retrieved 2024-03-05.
  2. 1 2 "Nadav Ahituv". Simons Institute for the Theory of Computing. Retrieved 2024-03-05.
  3. 1 2 "Speaker Template". PMWC Precision Medicine World Conference. Retrieved 2024-03-05.
  4. 1 2 "About · Ahituv Lab". Ahituv Lab. Retrieved 2024-03-05.
  5. Matharu, Navneet (2018-12-13). "CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency". Science. 363 (6424): eaau0629. doi:10.1126/science.aau0629. ISSN   1095-9203. PMID   30545847. S2CID   256746336.
  6. Matharu, Navneet; Ahituv, Nadav (2020-11-01). "Modulating gene regulation to treat genetic disorders". Nature Reviews Drug Discovery. 19 (11): 757–775. doi:10.1038/s41573-020-0083-7. ISSN   1474-1784. PMID   33020616. S2CID   256746336.
  7. Nguyen, Hai (2023-03-29). "Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression". bioRxiv. doi:10.1101/2023.03.28.534564. PMID   37034710.
  8. "Nadav Ahituv, PhD". UCSF Institute for Human Genetics. Retrieved 2024-03-05.
  9. Inoue, Fumitaka; Ahituv, Nadav (2015-09-01). "Decoding enhancers using massively parallel reporter assays". Genomics. 106 (3): 159–164. doi:10.1016/j.ygeno.2015.06.005. PMC   4540663 . PMID   26072433.
  10. "Nadav Ahituv, PhD | Department of Medicine". medicine.ucsf.edu. Retrieved 2024-03-05.
  11. "2024 ASHG Awards". American Society of Human Genetics. Retrieved 7 October 2024.